Avoid common mistakes on your manuscript.
Correction to: Cancer Chemother Pharmacol (2017) 80:1227–1237 https://doi.org/10.1007/s00280-017-3471-x
The author would like to correct the affiliations and conflict of interest in the publication of the original article. The corrected details are given below for your reading.
The affiliations should read as:
Jan de Jong1, Peter Hellemans2, James Juhui Jiao3, Yuhan Huang4, Sofie Mesens2, Juthamas Sukbuntherng5, Daniele Ouellet6
1Janssen Research and Development, LLC, San Diego, CA, USA
2Janssen Research and Development, LLC, Beerse, Belgium
3Janssen Research and Development, LLC, Raritan, NJ, USA
4Janssen Research and Development, LLC, Shanghai, China
5Pharmacyclics LLC, an AbbVie company, Sunnyvale, CA, USA
6Janssen Research and Development, LLC, Spring House, PA, USA
The conflict of interest section should read as:
Conflict of interest J de Jong, P Hellemans, JJ Jiao, Y Huang, S Mesens, and D Ouellet are employees of Janssen Research & Development, LLC. J Sukbuntherng is an employee of Pharmacyclics LLC, an AbbVie company.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1007/s00280-017-3471-x.
Rights and permissions
About this article
Cite this article
de Jong, J., Hellemans, P., Jiao, J.J. et al. Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study. Cancer Chemother Pharmacol 81, 423 (2018). https://doi.org/10.1007/s00280-017-3490-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-017-3490-7